J Immunother Cancer: Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer

Anti-PD1/PDL1 therapy has shown certain efficacy in recurrent ovarian cancer
.

Recently, foreign research teams have carried out related studies to evaluate the efficacy of Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Anti-PD1/PDL1 therapy has shown certain efficacy in recurrent ovarian cancer

This study is a phase I/II single-arm study to evaluate the efficacy of Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
.

Exclude patients with primary platinum resistance

This study is a phase I/II single-arm study to evaluate the efficacy of Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer

The study included 29 patients with a median age of 65 years (range: 41-80)

The most common treatment-related AEs are lymphopenia and anemia

Among the 29 patients treated, 10.

ORR

ORR

The median progression-free survival (PFS) was 4.
63 months (95% CI 4.
3-4.
96); the median OS was 11.
3 months (95% CI 6.
094-16.
506)
.

The median progression-free survival (PFS) was 4.
63 months (95% CI 4.
3-4.
96); the median OS was 11.
3 months (95% CI 6.
094-16.
506)
.

The median progression-free survival (PFS) was 4.

                     PFS and OS

PFS and OS

All patients with PD-L1 positive achieved PR (3/7, 42.
8%) or SD (4/7, 57.
2%)
.

However, PD-L1 positive and negative patients had PFS (median PFS in PD-L1+ patients was 4.

All patients with PD-L1 positive achieved PR (3/7, 42.

The median OS of patients with a baseline PD1 + Ki67 + CD8 + T cell ratio ≥0.

In summary, studies have shown that Pembrolizumab combined with low-dose carboplatin has good efficacy and tolerability in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
.

In summary, studies have shown that Pembrolizumab combined with low-dose carboplatin has good efficacy and tolerability in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
.

Studies have shown that Pembrolizumab combined with low-dose carboplatin has good efficacy and tolerability in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
.
Studies have shown that Pembrolizumab combined with low-dose carboplatin has good efficacy and tolerability in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers
.

Original source:

Original source:

Liao JB, Gwin WR,Urban RR, et al.
Pembrolizumab with low- dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Journal for ImmunoTherapy of Cancer 2021;9:e003122.
doi :10.
1136/jitc-2021-003122.

Liao JB, Gwin WR,Urban RR, et al.
Pembrolizumab with low- dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.
Journal for ImmunoTherapy of Cancer 2021;9:e003122.
doi :10.
1136/jitc-2021-003122.
Leave a message here